Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

NPA and Day Lewis defend PGD as DH and GPs raise concerns

Practice Pharmacy leaders have defended a patient group direction that allows the dispensing of 16 POMs – including antibiotics and inhalers – without a prescription, after the DH called a summit to discuss safety concerns.

Pharmacy leaders have defended an NPA scheme that allows the dispensing of 16 prescription-only medicines (POMs) without a prescription after the Department of Health (DH) and GPs raised concerns over the safety of the service.

The NPA, which developed the private patient group direction (PGD) service with Day Lewis, said it was "confident" that its "protocols improve access for people genuinely in need", after the DH requested a meeting to discuss the scheme.

Day Lewis, which has been piloting the scheme in pharmacies since October, also said it was confident that it was "both accessible and robust". 

The DH has requested a meeting with the NPA and Day Lewis to ensure patient safety was "not compromised" by the PGD

More on POMs

NPA service makes 16 POMs available without script

Get your POMs on eBay

Essex pair convicted for £500,000 illegal POM sale

The comments came after the DH said last week that chief pharmaceutical officer Keith Ridge had requested a meeting with the NPA and Day Lewis to discuss the PGD scheme.

It was important to ensure patient safety was "not compromised" by "getting medicines from other sources", a DH spokesperson said.

And "particular caution should be exercised in the use of antibiotics," the DH added. "Pharmacists should consider whether their inclusion in a patient group direction is absolutely necessary. This will make sure strategies to combat increasing antibiotic resistance are not put at risk."

But NPA director of pharmacy Deborah Evans said the scheme was "minimising" the risk of patients over-using antibiotics and patient feedback had so far been good.

She told C+D that the DH had requested further information about the four antibiotics featured in the PGD service and therefore, "as courtesy to the DH", participating pharmacies are not for now supplying trimethoprim, Zithromax, doxycycline and Ciproxin.

The British Medical Association's General Practitioners Committee (GPC) also raised concerns about the inclusion of asthma inhalers in the scheme. Chair of GPC's clincial and prescribing committee, Dr Bill Beeby said asthma patients could "run into trouble" if they weren't given the correct medical advice. 

"It's about being able to access appropriate medical advice, which is prevention rather than just [access to] a reliever. This is not an idle concern," he told C+D. 

But the NPA said it was about "emergency supply only". 

"This service helps to ensure patnnets have access to an important medicine for their symptom control, but they must have already been taking ventolin to qualify," Ms Evans said.   



Do you think the DH's concerns about the PGD are justified?

Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD015817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel